spacer
home > ict > autumn 2017 > teaming up
PUBLICATIONS
International Clinical Trials

Teaming Up

ICT: Your event claims it will provide discussions
regarding partnerships. What do these entail?


Louisa Maitland: Partnerships in Clinical Trials (PCT)
brings together groups of experts who are involved in
setting up, running and delivering trials; it is a meeting
place to discuss strategy, business and innovation.
Historically, PCT has mainly centred on the relationship
between the pharmaceutical or biotechnology company
and the CRO, but as the event has evolved over the
years, the focus has shifted. Today, a true partnership
will involve successful collaborations between sponsors,
CROs, regulators, investigators and, most importantly, the
patient. Communication and understanding of business
necessities are needed between all relevant parties, as
well as increasing operational efficiencies, streamlining
the development process, expanding global reach and
complementing internal knowledge with external expertise.

Throughout the industry, pharma and biotech
manufacturers, patient groups and policy makers are
continuing the mission to enhance collaborations with
subjects to align stakeholder needs and

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Louisa Maitland is Conference Director of PCT Europe, developing the event in partnership with the advisory board.
She completed an MSc at Kings College, UK, in forensic science and a BSc at Reading University, UK, in environmental science. After experience as both a Forensic Toxicologist and a Biochemist, for the last 16 years Louisa has worked in conference production, researching key trends and current challenges within various industry sectors, such as pharma, biotech and, most recently, clinical trials.
spacer
Louisa Maitland
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

BBI Solutions broadens antibody portfolio and strengthens reagent technical support capabilities with acquisition of Maine Biotechnology Services

BBI, a leading manufacturer of raw materials and finished test platforms, already provides human antigens, antibodies, serum and plasma products and clinical chemistry enzymes, for the in-vitro diagnostics market. Now with the acquisition of MBS they have strengthened their antibody offering, providing a comprehensive portfolio and custom services to deliver a total reagent solution for any immunoassay development.
More info >>

White Papers

Advanced BioDesign Outlines Solutions

Advanced BioDesign

Launching an immunisation programme is an important experimental step that needs care. With Advanced BioDesign, clients may develop and produce antibodies according to customers' specific needs. The company offers: real support and advice from a dedicated team all along your project; large and modern SPF animal facility; ethical treatment of animals. The evaluation of a project is free-of-charge and with no obligation. Dedicated project managers will work with clients from the beginning to the end of a custom antibody project to ensure the highest level of quality and service.
More info >>

 
Industry Events

3D Cell Culture 2018

21-22 February 2018, Holiday Inn Kensington Forum, London UK

Building on the sell-out success of the launch event, SMi Group is delighted to announce the return of 3D Cell Culture, taking place on 21st and 22nd of February 2018, in London UK.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement